Svb Leerink Comments on Rocket Pharmaceuticals Inc’s Q1 2020 Earnings (NASDAQ:RCKT)

Rocket Pharmaceuticals Inc (NASDAQ:RCKT) – Equities researchers at Svb Leerink issued their Q1 2020 earnings per share estimates for Rocket Pharmaceuticals in a report issued on Thursday, December 5th. Svb Leerink analyst M. Foroohar anticipates that the biotechnology company will post earnings of ($0.55) per share for the quarter. Svb Leerink also issued estimates for Rocket Pharmaceuticals’ Q2 2020 earnings at ($0.55) EPS, Q3 2020 earnings at ($0.50) EPS and Q4 2020 earnings at ($0.50) EPS.

Rocket Pharmaceuticals (NASDAQ:RCKT) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.11.

Other analysts have also recently issued research reports about the company. Zacks Investment Research cut Rocket Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, October 26th. ValuEngine lowered shares of Rocket Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Cowen restated a “buy” rating on shares of Rocket Pharmaceuticals in a report on Sunday, November 17th. Oppenheimer decreased their price target on shares of Rocket Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 13th. Finally, Piper Jaffray Companies assumed coverage on shares of Rocket Pharmaceuticals in a report on Thursday, September 26th. They set an “overweight” rating for the company. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $31.50.

Shares of NASDAQ:RCKT opened at $22.37 on Friday. The company has a quick ratio of 11.07, a current ratio of 11.07 and a debt-to-equity ratio of 0.20. The company has a market capitalization of $1.13 billion, a P/E ratio of -11.83 and a beta of 2.78. Rocket Pharmaceuticals has a 52-week low of $10.75 and a 52-week high of $24.42. The stock’s fifty day simple moving average is $15.56 and its 200-day simple moving average is $13.98.

Several hedge funds have recently bought and sold shares of RCKT. Metropolitan Life Insurance Co NY increased its stake in Rocket Pharmaceuticals by 43.4% in the third quarter. Metropolitan Life Insurance Co NY now owns 10,616 shares of the biotechnology company’s stock valued at $124,000 after purchasing an additional 3,213 shares during the last quarter. Eventide Asset Management LLC lifted its holdings in shares of Rocket Pharmaceuticals by 42.3% during the 3rd quarter. Eventide Asset Management LLC now owns 1,415,000 shares of the biotechnology company’s stock worth $16,485,000 after acquiring an additional 420,686 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of Rocket Pharmaceuticals by 1,107.4% in the third quarter. Tower Research Capital LLC TRC now owns 4,250 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 3,898 shares during the last quarter. Comerica Bank boosted its position in shares of Rocket Pharmaceuticals by 35.2% in the third quarter. Comerica Bank now owns 28,155 shares of the biotechnology company’s stock worth $363,000 after acquiring an additional 7,329 shares during the last quarter. Finally, California Public Employees Retirement System acquired a new stake in shares of Rocket Pharmaceuticals in the third quarter worth approximately $168,000. Institutional investors and hedge funds own 93.86% of the company’s stock.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; and leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction It also has additional pre-clinical stage LVV programs include pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption.

Read More: Short Selling

Earnings History and Estimates for Rocket Pharmaceuticals (NASDAQ:RCKT)

Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.